CURRENT LISTING OF CLAIMS

Claims 1-24 (cancelled).

25. (**Previously presented**) A conjugate comprising a Substance P analog and a polypeptide that inhibits protein synthesis, wherein the analog is selected from CYGGGGGGRPKPQQFF SarLMet(O_2)-amide (SEQ ID NO:1) and CYGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).

26. (**Previously presented**) The conjugate of claim 25, wherein said analog of Substance P is CYGGGGGGRPKPQQFF SarLMet(O_2)-amide (SEQ ID NO:1).

27. (**Previously presented**) The conjugate of claim 25, wherein said analog of Substance P is CYGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).

28. (**Previously presented**) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is attached to said Substance P analog through a disulfide linkage.

29. (**Previously presented**) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is saporin.

30. (**Previously presented**) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is a ribosome-inactivating protein.

31. (**Previously presented**) The conjugate of claim 30, wherein said ribosome-inactivating protein is selected from ricin A chain, gelonin and pokeweed antiviral protein.

32. (**Previously presented**) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is a toxin.

33. (**Previously presented**) The conjugate of claim 32, wherein said toxin is diphtheria toxin A fragment or an analog thereof that inhibits protein synthesis.

34. (**Previously presented**) The conjugate of claim 32, wherein said toxin is pseudomonas aeruginosa exotoxin A fragment or an analog thereof that inhibits protein synthesis.

35. (**Previously presented**) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 25, and a pharmaceutically acceptable carrier.

36. (**Previously presented**) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 29, and a pharmaceutically acceptable carrier.

37. (**Previously presented**) The conjugate of claim 31, wherein said ribosome-inactivation protein is ricin A chain.

38. (**Previously presented**) The conjugate of claim 31, wherein said ribosome-inactivation protein is gelonin.

39. (**Previously presented**) The conjugate of claim 31, wherein said ribosome-inactivation protein is pokeweed antiviral protein.

40. (**Previously presented**) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is attached to said Substance P analog through a chemical bond.

41-56. (**Cancelled**)